# AL Amyloidosis and Anti-CD38-Daratunumab

> **NCT06571864** · NA · COMPLETED · sponsor: **University of Turin, Italy** · enrollment: 14 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Anti-CD38 Monoclonal Antibody

## Key facts

- **NCT ID:** NCT06571864
- **Lead sponsor:** University of Turin, Italy
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-02
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-02-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06571864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06571864, "AL Amyloidosis and Anti-CD38-Daratunumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06571864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*